MedTrace Logo

A Study of Telitacicept in Lupus Nephritis

NCT05680480 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-09-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.

Conditions

Interventions

BIOLOGICAL

Telitacicept 240 mg

Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.

BIOLOGICAL

Telitacicept 160 mg

Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.

DRUG

Placebo

Participants will receive placebo weekly in addition to SOC for 48 weeks.

Sponsors & Collaborators

  • RemeGen Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2025-12-31
Completion
2026-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05680480 on ClinicalTrials.gov